Test Price
2,000 AED✅ Home Collection Available
ONCOPRO KRAS Rapid Test in UAE | 2000 AED | 2026 DHA Guidelines
تحليل طفرة KRAS الجينية ONCOPRO السريع في الإمارات | 2000 درهم إماراتي | دقة تشخيصية 99.9% | معتمد من هيئة الصحة بدبي 2026
Executive Summary & UAE Trust Signals
ملخص تنفيذي: اختبار ONCOPRO KRAS السريع هو تحليل جزيئي متطور يكشف عن الطفرات الجينية في جين KRAS باستخدام تقنية تفاعل البوليميراز المتسلسل في الوقت الحقيقي (Real-Time PCR/qPCR). يُجرى هذا الفحص على عينات الأنسجة المثبتة بالفورمالين والمضمنة بالبرافين (FFPE) في مختبراتنا المعتمدة وفق أعلى معايير الجودة العالمية ISO 9001:2015 (الشهادة رقم: INT/EGQ/2509DA/3139). تظهر النتائج خلال يوم عمل واحد بدقة تشخيصية تصل إلى 99.9%، مما يساعد أطباء الأورام في دولة الإمارات العربية المتحدة على تحديد خطة العلاج المناسبة والموجهة للمرضى المصابين بسرطان القولون والمستقيم والرئة والبنكرياس. نلتزم امتثالاً كاملاً للمرسوم بقانون اتحادي رقم 41 لسنة 2024 (المادة 87) وقانون CDS 2026 للقُصَّر وقانون حماية البيانات الشخصية الإماراتي (PDPL).
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM, Dubai & Northern Emirates).
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation by DHA-Certified Oncology Liaison Team.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731. Accepted by all major UAE insurers including Daman, AXA, Oman Insurance, and Neuron.
Overview: Precision KRAS Mutation Analysis for Targeted Oncology
The ONCOPRO KRAS Rapid Test provides definitive detection of clinically actionable KRAS gene mutations — including codons 12, 13, 61, and 146 — from formalin-fixed paraffin-embedded (FFPE) tumor tissue. هذا التحليل الجيني ضروري لتحديد ما إذا كان المريض مؤهلاً للعلاج الموجه بمضادات مستقبلات عامل النمو البشروي (anti-EGFR therapy)، خاصة في حالات سرطان القولون والمستقيم النقيلي وسرطان الرئة غير صغير الخلايا وسرطان البنكرياس. Results inform critical therapeutic decisions, preventing futile administration of cetuximab or panitumumab in KRAS-mutant colorectal carcinoma.
| Parameter | Our Test: ONCOPRO KRAS Rapid | Closest Alternative: NGS Panel / Sanger Sequencing |
|---|---|---|
| Precision (Analytical Sensitivity) | 99.9% — Detects mutant alleles at ≤1% variant allele frequency (VAF) | 95–98% — VAF detection limit typically 5–10% |
| Methodology | Real-Time PCR (qPCR) — Gold standard, closed-tube, contamination-free | Sanger Sequencing or Broad NGS Panel — longer workflows, higher cost |
| Turnaround Time | Next Working Day (sample received by 11 AM) | 7–14 Days |
| Tissue Requirement | FFPE Block with ≥10% tumor tissue | FFPE Block or 10–15 unstained slides; often ≥20% tumor required |
| Cost (UAE) | 2,000 AED | 3,500–8,000 AED |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy, DHA License: 61713011 — "As a clinical oncologist, I understand that waiting for KRAS mutation results can be an emotionally intense period for patients and their families. This test is not merely a laboratory value; it is a critical decision node that determines whether anti-EGFR monoclonal antibody therapy will benefit the patient or expose them to unnecessary toxicity without clinical gain. I urge every patient to interpret these results in close consultation with their treating oncologist — a positive KRAS mutation finding directs us toward alternative, equally potent therapeutic strategies, while a wild-type result opens the door to targeted biologic agents that have transformed metastatic colorectal cancer outcomes."
⚠ MEDICATION NOTICE: Do not discontinue, modify, or adjust any prescribed medication — including chemotherapy, targeted therapy, or supportive care — based on this test result without consulting your treating physician. KRAS mutation status informs future treatment strategy and does not independently warrant immediate changes to ongoing therapy.
Safety Exclusion Criteria & Emergency Red Flags
Specimen Rejection Criteria
- FFPE block with less than 10% tumor tissue content (insufficient neoplastic cells for reliable PCR amplification).
- Improperly fixed tissue (fixation delayed beyond 6 hours post-excision or fixation duration less than 6 hours).
- Decalcified tissue specimens (acid-based decalcification degrades DNA integrity).
- Block submitted without corresponding H&E-stained slide for pathological review.
- Specimen container unlabeled or mismatched with requisition form.
Patient Emergency Red Flags (Seek Immediate Medical Attention)
- New-onset severe abdominal pain, obstruction symptoms, or inability to pass stool.
- Acute shortness of breath, chest pain, or hemoptysis in known or suspected lung cancer.
- Jaundice, intractable vomiting, or signs of biliary obstruction in pancreatic cancer.
- Fever ≥38.5°C with neutropenia (if on active chemotherapy).
- Any acute neurological change, seizure, or focal weakness.
If you experience any of the above, proceed to the nearest Emergency Department immediately. This laboratory test result does not replace urgent clinical evaluation.
Patient FAQ & Clinical Guidance
Q: What is the ONCOPRO KRAS Rapid Test and why has my oncologist ordered it?
The ONCOPRO KRAS Rapid Test detects specific genetic mutations in the KRAS gene from your tumor tissue to guide targeted cancer therapy decisions. KRAS mutations are found in approximately 40% of colorectal cancers, 30% of non-small cell lung cancers, and over 90% of pancreatic cancers. When your tumor harbors a KRAS mutation, anti-EGFR therapies such as cetuximab and panitumumab are ineffective and may cause harm without benefit. Your oncologist ordered this to ensure you receive only treatments proven to work against your specific tumor biology — a cornerstone of precision oncology in the UAE under DHA 2026 clinical standards.
Q: How must the FFPE tissue block be prepared and submitted for accurate KRAS testing?
Submit a formalin-fixed paraffin-embedded tissue block containing at least 10% tumor tissue, shipped at room temperature with a corresponding H&E slide for pathology review. The tissue block must be obtained from your most recent biopsy or surgical resection. Our laboratory accepts samples daily until 11 AM; results are reported the next working day. The FFPE block should be placed in a sealed biohazard specimen bag with the completed requisition form and transported via our ISO-certified cold-chain courier service. If the block is archived at an external hospital, our medical liaison team can coordinate retrieval on your behalf — contact +971 54 548 8731 for assistance.
س: كم من الوقت يستغرق الحصول على نتيجة تحليل KRAS وماذا تعني النتيجة الإيجابية؟
تظهر نتائج تحليل KRAS خلال يوم عمل واحد بدقة 99.9%، والنتيجة الإيجابية تعني وجود طفرة تجعل العلاج الموجه بمضادات EGFR غير فعال. إذا كانت النتيجة إيجابية لطفرة KRAS، فهذا يشير إلى أن الخلايا السرطانية تحمل تغيراً جينياً يمنع استجابتها للعلاجات البيولوجية مثل سيتوكسيماب وبانيتوموماب، وسيختار طبيب الأورام المعالج علاجات بديلة مثل العلاج الكيميائي التقليدي أو مثبطات VEGF مثل بيفاسيزوماب. أما النتيجة السلبية (KRAS Wild-Type) فتعني أن الورم قابل للاستجابة للعلاج الموجه بمضادات EGFR، مما يفتح خيارات علاجية فعالة ومثبتة سريرياً. يُرجى مناقشة النتيجة مع طبيب الأورام المعالج لتفسيرها في سياق حالتك السريرية الكاملة وخطة العلاج الشاملة.
Clinical Entity Coding & Regulatory References (2026)
This page is reviewed and updated quarterly in accordance with DHA Circular No. 43 of 2026. Last Clinical Review: June 2026. © 2026. All rights reserved. Content is for informational purposes and does not constitute medical advice.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians